retatrutide peptide clinical trials Today, we shared new data from two Phase 3 of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide Significantly Reduces Visceral Fat

The study was sponsored by Eli Lilly and Company, the manufacturer of orforglipron and the injectable GLP-1 tirzepatide

Start the dietary elimination phase (remove eggs, cruciferous vegetables, garlic, onions, carbonated drinks, sugar-free gum)

Liraglutide In an observational study, 52 weeks of liraglutide treatment was shown to increase the glomerular filtration rate (GFR) (5.4 ml/min/1.73 m 2 ) and reduce albuminuria by 50% in overweight T2D patients with stage 3 CKD (Von Scholten et al., 2017)

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of prescription medications that mimic the effects of the natural GLP-1 hormone and help control blood sugar levels, slow digestion, and regulate appetite

Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers Legal Alerts 2.12.26 Takeaways The bill would limit 503A pharmacies from compounding large volumes of drugs that are essentially copies of commercially available FDA-approved products

[1] [2] It belongs to a novel class of drugs known as triple receptor agonists, distinguishing it from earlier-generation weight-loss medications